HC Wainwright Issues Optimistic Forecast for Ocugen Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Equities research analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of Ocugen in a research note issued to investors on Monday, September 28th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.27) per share for the year, up from their prior estimate of ($0.28). The consensus estimate for Ocugen’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Ocugen’s Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at ($0.39) EPS and FY2030 earnings at $0.99 EPS.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0.89 million.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings upgraded Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of Ocugen from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Ocugen presently has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Ocugen Stock Up 5.8%

Shares of NASDAQ:OCGN opened at $1.09 on Wednesday. The business’s 50 day moving average is $1.24 and its 200 day moving average is $1.46. Ocugen has a 12-month low of $0.97 and a 12-month high of $2.73. The stock has a market cap of $369.63 million, a price-to-earnings ratio of -4.19 and a beta of 2.20. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 4.17.

Insiders Place Their Bets

In related news, CEO Shankar Musunuri sold 468,727 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $1.12, for a total transaction of $524,974.24. Following the completion of the sale, the chief executive officer owned 4,487,197 shares in the company, valued at approximately $5,025,660.64. This trade represents a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.95% of the company’s stock.

Institutional Trading of Ocugen

Several hedge funds have recently made changes to their positions in OCGN. Engineers Gate Manager LP grew its stake in shares of Ocugen by 70.2% during the 2nd quarter. Engineers Gate Manager LP now owns 18,368 shares of the company’s stock worth $28,000 after acquiring an additional 7,577 shares during the period. NewEdge Advisors LLC lifted its holdings in Ocugen by 42.4% during the second quarter. NewEdge Advisors LLC now owns 237,180 shares of the company’s stock valued at $363,000 after purchasing an additional 70,585 shares during the last quarter. AXQ Capital LP bought a new position in Ocugen during the second quarter worth about $65,000. Headlands Technologies LLC boosted its position in Ocugen by 527.1% during the second quarter. Headlands Technologies LLC now owns 511,575 shares of the company’s stock worth $783,000 after purchasing an additional 429,997 shares during the period. Finally, Two Sigma Securities LLC increased its stake in shares of Ocugen by 116.9% in the second quarter. Two Sigma Securities LLC now owns 156,027 shares of the company’s stock worth $239,000 after purchasing an additional 84,100 shares in the last quarter. 10.27% of the stock is currently owned by institutional investors.

Key Headlines Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts. The firm improved its estimates for FY2026, FY2027, FY2028, and the second through fourth quarters of 2027, reflecting expectations for narrower losses. Its FY2030 forecast also increased to $0.99 earnings per share from $0.98, suggesting potential long-term profitability. Ocugen analyst estimates
• Positive Sentiment: Ocugen announced presentations at upcoming scientific conferences. Management will highlight its modifier gene therapy platform for blindness-related diseases, providing an opportunity to increase visibility with researchers, investors, and potential partners. However, the announcement did not include new clinical or regulatory results. Ocugen scientific conferences announcement
• Neutral Sentiment: Investor and industry conference appearances could support awareness. Ocugen executives are scheduled to participate in October events, including an H.C. Wainwright conference, but the company provided no specific financing, partnership, or development update. Ocugen October conference announcement
• Negative Sentiment: Ocugen is still expected to report substantial losses. HC Wainwright forecasts negative EPS of $0.27 for FY2026, $0.32 for FY2027, and $0.39 for FY2028. The firm also trimmed its FY2029 estimate to $0.05 from $0.06, tempering the otherwise favorable revisions. With a negative trailing P/E and a quick ratio of 0.80, profitability and funding remain key risks.

Ocugen Company Profile

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and other serious medical conditions. The company’s ophthalmology pipeline includes modifier gene therapies designed to address inherited retinal diseases, including retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration.

Ocugen’s leading candidates include OCU400, an investigational gene therapy for certain inherited retinal diseases, and OCU410 and OCU410ST, investigational therapies being developed for geographic atrophy and Stargardt disease, respectively.